Impact of the COVID-19 pandemic on cardiovascular heart disease medication use: time-series analysis of England's prescription data during the COVID-19 pandemic (January 2019 to October 2020)
CONCLUSION: A concerning decline in uptake of CVD therapies for chronic heart disease was observed. Accessible screening and treatment alongside financial relief on prescription levies are needed. A video abstract is (4 min 51 s) available: https://bit.ly/39gvEHi.PMID:36420815 | DOI:10.1177/17539447221137170 (Source: Adv Data)
Source: Adv Data - November 24, 2022 Category: Epidemiology Authors: Ravina Barrett James Hodgkinson Source Type: research

Identification and Validation of Potential Genotoxic Impurities, 1,3-Dichloro-2-Propanol, and 2,3-Dichloro-1-Propanol, at subtle levels in bile acid sequestrant, Colesevelam Hydrochloride using hyphenated GC-MS technique
Biomed Chromatogr. 2022 Oct 17:e5528. doi: 10.1002/bmc.5528. Online ahead of print.ABSTRACTPotential Genotoxic Impurities (PGI) and N-nitrosamine impurities in APIs and their determination at the low level are substantial challenges for Cholesterol-lowering agents in recent years. Herein we developed a robust, reliable, rapid, accurate, and validated technique of Gas Chromatography equipped with a Mass Spectrometer (GC-MS) for quantifying subtle levels of 1,3-Dichloro-2-Propanol (PGI-I) and 2,3-Dichloro-1-Propanols (PGI-II) in Colesevelam Hydrochloride drug substance (bile acid sequestrant). The separation of Colesevelam H...
Source: Biomedical Chromatography : BMC - October 17, 2022 Category: Biomedical Science Authors: S R Jythesh Kumar Junuthula Venkata Ramana Reddy Vandavasi Koteswara Rao Source Type: research

Identification and Validation of Potential Genotoxic Impurities, 1,3-Dichloro-2-Propanol, and 2,3-Dichloro-1-Propanol, at subtle levels in bile acid sequestrant, Colesevelam Hydrochloride using hyphenated GC-MS technique
Biomed Chromatogr. 2022 Oct 17:e5528. doi: 10.1002/bmc.5528. Online ahead of print.ABSTRACTPotential Genotoxic Impurities (PGI) and N-nitrosamine impurities in APIs and their determination at the low level are substantial challenges for Cholesterol-lowering agents in recent years. Herein we developed a robust, reliable, rapid, accurate, and validated technique of Gas Chromatography equipped with a Mass Spectrometer (GC-MS) for quantifying subtle levels of 1,3-Dichloro-2-Propanol (PGI-I) and 2,3-Dichloro-1-Propanols (PGI-II) in Colesevelam Hydrochloride drug substance (bile acid sequestrant). The separation of Colesevelam H...
Source: Biomedical Chromatography : BMC - October 17, 2022 Category: Biomedical Science Authors: S R Jythesh Kumar Junuthula Venkata Ramana Reddy Vandavasi Koteswara Rao Source Type: research

Identification and Validation of Potential Genotoxic Impurities, 1,3-Dichloro-2-Propanol, and 2,3-Dichloro-1-Propanol, at subtle levels in bile acid sequestrant, Colesevelam Hydrochloride using hyphenated GC-MS technique
Biomed Chromatogr. 2022 Oct 17:e5528. doi: 10.1002/bmc.5528. Online ahead of print.ABSTRACTPotential Genotoxic Impurities (PGI) and N-nitrosamine impurities in APIs and their determination at the low level are substantial challenges for Cholesterol-lowering agents in recent years. Herein we developed a robust, reliable, rapid, accurate, and validated technique of Gas Chromatography equipped with a Mass Spectrometer (GC-MS) for quantifying subtle levels of 1,3-Dichloro-2-Propanol (PGI-I) and 2,3-Dichloro-1-Propanols (PGI-II) in Colesevelam Hydrochloride drug substance (bile acid sequestrant). The separation of Colesevelam H...
Source: Biomedical Chromatography : BMC - October 17, 2022 Category: Biomedical Science Authors: S R Jythesh Kumar Junuthula Venkata Ramana Reddy Vandavasi Koteswara Rao Source Type: research

Colesevelam - a bile acid sequestrant for treating hypercholesterolemia and improving hyperglycemia
Expert Opin Pharmacother. 2022 Aug 15. doi: 10.1080/14656566.2022.2112945. Online ahead of print.ABSTRACTINTRODUCTION: Low density Lipoprotein cholesterol)LDL-C) levels show a clear relationship with cardiovascular disease (CVD). Statins are first line agents to reduce LDL-C and CVD risk. However, combination lipid-lowering therapy is often required to achieve large reductions in LDL-C.AREA COVERED: Colesevelam HCl is a bile acid sequestrant (BAS), which reduces LDL-C by 16-22% in monotherapy and adds a further 12-14% reduction in LDL-C when combined with other lipid-lowering drugs. Like statins, colesevelam reduces C-reac...
Source: Expert Opinion on Pharmacotherapy - August 15, 2022 Category: Drugs & Pharmacology Authors: Oluwayemisi Esan Adie Viljoen Anthony S Wierzbicki Source Type: research

Incidence, Diagnosis and Management of Malabsorption Following Oesophagectomy: a Systematic Review
ConclusionsMalabsorption syndromes following oesophagectomy are under-recognised, and thus under-reported. The resultant gastrointestinal symptoms may have a negative effect on post-operative quality of life. Current literature suggests benefit with outlined therapies; however, greater understanding of these conditions, their diagnosis and management is required to further understand which patients will benefit from treatment. (Source: Journal of Gastrointestinal Surgery)
Source: Journal of Gastrointestinal Surgery - April 28, 2022 Category: Surgery Source Type: research

The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia
AbstractPurpose of ReviewLifestyle modification is additive to lipid-lowering medications in the treatment of heterozygous familial hypercholesterolemia (HeFH), which does not respond sufficiently to statin therapy. While both are also important in homozygous familial hypercholesterolemia (HoFH), additional measures such as apheresis may be needed. The purpose of this review is to identify non-statin medications to lower cholesterol that are available for children and adolescents as adjunctive therapy.Recent FindingsEzetimibe is commonly used as second-line pharmacotherapy for treatment of HeFH and HoFH. Colesevelam, a bil...
Source: Current Atherosclerosis Reports - March 28, 2022 Category: Cardiology Source Type: research

Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice
ConclusionsColesevelam ameliorates Western diet-induced steatohepatitis and obesity in microbiome-humanized mice. (Source: Hepatology International)
Source: Hepatology International - January 24, 2022 Category: Infectious Diseases Source Type: research

Cancers, Vol. 13, Pages 6213: Bile Acid Malabsorption as a Consequence of Cancer Treatment: Prevalence and Management in the National Leading Centre
arina Kohoutova The aim was to establish prevalence of bile acid malabsorption (BAM) and management in patients who underwent treatment for malignancy. Retrospective evaluation of data in patients seen within six months (August 2019–January 2020) was carried out. Demographic, nuclear medicine (Selenium Homocholic Acid Taurine (SeHCAT) scan result), clinical (previous malignancy, type of intervention (medication, diet), response to intervention) and laboratory (vitamin D, vitamin B12 serum levels) data were searched. In total, 265 consecutive patients were reviewed. Out of those, 87/265 (33%) patients (57 ...
Source: Cancers - December 10, 2021 Category: Cancer & Oncology Authors: Caroline Gee Catherine Fleuret Ana Wilson Daniel Levine Ramy Elhusseiny Ann Muls David Cunningham Darina Kohoutova Tags: Article Source Type: research

Colesevelam ‐induced hypoglycaemia in a patient with type 1 diabetes mellitus
Colesevelam possesses antidiabetic properties, which could potentiate sulphonylurea or insulin-induced hypoglycemia; clinically significant hypoglycemia, as a side effect to bile acid sequestrants, may be under-recognized in clinical practice. AbstractColesevelam possesses antidiabetic properties, which could potentiate sulphonylurea or insulin-induced hypoglycemia; clinically significant hypoglycemia, as a side effect to bile acid sequestrants, may be under-recognized in clinical practice. (Source: Clinical Case Reports)
Source: Clinical Case Reports - October 15, 2021 Category: General Medicine Authors: Panagiotis Pavlou, Vaios Koutroukas, Catherine Lissett, Jamie C. Smith Tags: CASE REPORT Source Type: research

Effects of Manipulating Circulating Bile Acid Concentrations on Postprandial GLP-1 Secretion and Glucose Metabolism After Roux-en-Y Gastric Bypass
ConclusionIn RYGB-operated persons, exogenous CDCA enhanced meal-stimulated GLP-1 and glucagon secretion but not insulin secretion, while the BA sequestrant colesevelam decreased CDCA-stimulated GLP-1 secretion but did not affect meal-stimulated GLP-1, C-peptide or glucagon secretion, or glucose tolerance. These findings suggest a limited role for endogenous bile acids in the acute regulation of postprandial gut hormone secretion or glucose metabolism after RYGB. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - May 14, 2021 Category: Endocrinology Source Type: research

Regional variability in Canadian routine care of type 2 diabetes, hypercholesterolemia, and hypertension: Results from the The Cardio-Vascular and metabolic treatments in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry.
CONCLUSION: This is the first regional description of the CV-CARE cohort. Significant variations in both baseline profile and treatments were observed which could have an impact on long-term outcomes. PMID: 32473770 [PubMed - as supplied by publisher] (Source: Journal of Cardiology)
Source: Journal of Cardiology - May 26, 2020 Category: Cardiology Authors: Goldenberg R, Bell A, Cheng W, Paron E, Fils-Aimé N, Burrows M, Blavignac J, Barakat M Tags: J Cardiol Source Type: research

Table: Safety of Drugs for IBS in Pregnancy and Lactation (online only)
Date: March 23, 2020 Issue #:  1594Summary:  View the Table: Safety of Drugs for IBS in Pregnancy and Lactation (Source: The Medical Letter)
Source: The Medical Letter - March 13, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Alosetron amitiza Amitriptyline bentyl Celexa Cholestyramine Citalopram Colesevelam Colestid Colestipol Desipramine dicyclomine eluxadoline fluoxetine Hyoscyamine Ibsrela irritable bowel syndrome Levsin linaclotide Li Source Type: research